__NUXT_JSONP__("/drugs/Autologous_Mesothelin-specific_Human_mRNA_CAR-transfected_PBMCs_MCY-M11", (function(a,b,c,d){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"Autologous peripheral blood mononuclear cells (PBMCs) transfected with anti-mesothelin chimeric antigen receptor (CAR) mRNA, with potential antineoplastic activity. Upon intraperitoneal (IP) administration, the autologous mesothelin-specific human mRNA CAR-transfected PBMCs MCY-M11 recognize, bind to, phagocytose and directly kill cancer cells expressing mesothelin. In addition, MCY-M11 stimulates the immune system to induce a cytotoxic T-lymphocyte response against the mesothelin-expressing cancer cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in many epithelial-derived cancers.",fdaUniiCode:"ER09HM7LIR",identifier:"C155775",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C307","C308"],synonyms:["Anti-mesothelin mRNA-transfected Autologous PBMCs MCY-M11",c,"MCY-M11"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FAutologous_Mesothelin-specific_Human_mRNA_CAR-transfected_PBMCs_MCY-M11",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("","Autologous_Mesothelin-specific_Human_mRNA_CAR-transfected_PBMCs_MCY-M11","Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11","2021-10-30T13:34:12.673Z")));